SL Science
WHERE TREATMENT BEGINS BEYOND LIMITS
Cell therapy is one of the most promising advances in cancer treatment, yet global scale has remained out of reach due to high costs, limited capacity, and lack of standardization.
SL Science Holding Limited ("SLBT Group") ’s GDT platform applies industrial-scale logic to cell therapy, transforming it into a standardized, scalable, and reproducible global platform.
Gamma delta (γδ) T cell is more than a therapy—it is shaping the future of immune-based medicine.
Our Story
SLBT Group is dedicated to advancing groundbreaking cell and gene therapies while expanding its established portfolio in regenerative medicine and oncology.
Our research concentrates on investigational immune cell technologies currently in preclinical development, including proprietary Armed-T and gamma delta (γδ) T cells, as well as a novel exosome portfolio formulated from non-human sources such as plants and bovine milk.
These parallel efforts position the Company at the intersection of translational immunology and early-stage regenerative science. In 2024, SLBT Group completed a strategic capital raise and investment framework restructuring to support long-term growth across both immune-based R&D programs and non-therapeutic formulation initiatives.
Our Vision &
Commitment
SLBT Group’s vision is to contribute to the future of healthcare by advancing research-driven innovation in immune cell science and non-cellular biologics. Our work is focused on supporting the development of preclinical platforms, both cell-based and cell-free, designed for investigational use across oncology and regenerative research applications.
We are committed to ethical research, scientific transparency, and responsible innovation. Our development efforts include immune cell redirection platforms and exosome-based formulation systems sourced from plant and milk-derived materials, with applications in both cancer research and topical formulation science.
Through sustained investment in early-stage R&D and collaborative partnerships, the Company aims to deliver high-integrity innovation that aligns with long-term goals in translational research and global scientific advancement.
News
11 F., No. 479, Chongyang Rd., Nangang Dist., Taipei City 115, Taiwan
E-mail: ir@slbtgroup.com
TaiwanTel: +886-2-26516826